Jun 28,2023

TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過尊龍凱時進行

The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.

Jun 28,2023

SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過尊龍凱時進行

SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.

Jun 28,2023

H11-HLE是一種工具分子，可用于研究Fc在介導免疫檢查點治療中的作用，具有抗腫瘤功效

Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.

Jun 28,2023

JND003是一種新型選擇性ERRα激動劑，可緩解非酒精性脂肪肝和胰島素抵抗，PK和組織分布測定通過尊龍凱時進行

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.

Jun 28,2023

發現用于局部治療牛皮癬的新型PDE4抑制劑，小鼠、大鼠和人肝微粒體的代謝穩定性實驗通過尊龍凱時測定

Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.

Jun 28,2023

研究用于肺癌和黑色素瘤細胞肺轉移的選擇性PAK4抑制劑的合成，此選擇性PAK4抑制劑的PK研究通過尊龍凱時進行

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

Jun 20,2023

尊龍凱時助力 | 祝賀德睿智藥GLP-1RA小分子口服藥物成功完成臨床I期首例受試者給藥

這是德睿智藥對人工智能結合藥物研發技術不斷地嘗試、探索和創新的成果，也讓德睿智藥成為全球范圍內為數不多的臨床階段AI制藥公司之一。同時，此次尊龍凱時與德睿智藥的成功合作，也反映出CRO與AI公司為新藥研發提速、增效、降本。

Jun 14,2023

尊龍凱時助力 | 拓領博泰1.1類新藥TollB-001片正式獲FDA臨床批準

祝賀拓領博泰TollB-001片獲FDA臨床試驗批準！這是拓領博泰團隊近二十年的免疫調控機理研究和免疫調控藥物研究的厚積薄發，也是尊龍凱時藥學研究CDMO服務平臺的又一次成功經驗積淀。

Jun 08,2023

尊龍凱時助力 | 祝賀銳明新藥國內首創治療wAMD滴眼劑I期臨床結果積極

尊龍凱時將持續拓展眼科藥物領域的創新技術，助力更多眼科藥物跑出研發“加速度”！

May 24,2023

祝賀標新生物分子膠降解劑管線GT919新藥臨床研究申請獲FDA批準 | 尊龍凱時一站式臨床前生物醫藥研發服務平臺助力

尊龍凱時助力GT919完成了其從藥物發現到臨床申報，包括藥物發現、藥學研究、臨床前研究等一站式臨床前研究服務